• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

乳腺癌干细胞及其在抗内分泌治疗中的作用。

Breast cancer stem cells and their role in resistance to endocrine therapy.

机构信息

School of Cancer and Imaging Sciences, Paterson Institute for Cancer Research, University of Manchester, Manchester, M20 4BX, UK.

出版信息

Horm Cancer. 2011 Apr;2(2):91-103. doi: 10.1007/s12672-011-0066-6.

DOI:10.1007/s12672-011-0066-6
PMID:21761332
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10358078/
Abstract

Developmentally, tumours can be viewed as aberrant versions of normal tissues. For example, tumours often retain differentiation markers of their tissue of origin. In addition, there is evidence that they contain cancer stem-like cells (CSCs) that drive tumourigenesis. In this review, we summarise current evidence that breast CSCs may partially explain endocrine resistance in breast cancer. In normal breast, the stem cells are known to possess a basal phenotype and to be mainly oestrogen receptor-α-negative (ER-). If the hierarchy in breast cancer reflects this, the breast CSC may be endocrine resistant because it expresses very little ER and can only respond to treatment by virtue of paracrine signalling from neighbouring, differentiated ER+ tumour cells. Normal breast epithelial stem cells are regulated by the epidermal growth factor receptor and other growth factor receptor signals. The observed increase in growth factor receptor expression in endocrine-resistant breast cancers may reflect a bigger proportion of CSCs selected by endocrine therapies. There is evidence from a number of studies that breast CSCs are ER- and EGR+/HER2+, which would support this view. It is reported that CSCs express mesenchymal genes, which are suppressed by ER expression, further indicating the mutual exclusion between ER+ cells and the CSCs. As we learn more about CSCs, differentiation and the expression and functional activity of the ER in these cells in diverse breast tumour sub-types, it is hoped that our understanding will lead to new modalities to overcome the problem of endocrine resistance in the clinic.

摘要

从发育的角度来看,肿瘤可以被视为正常组织的异常版本。例如,肿瘤通常保留其起源组织的分化标志物。此外,有证据表明它们含有驱动肿瘤发生的癌症干细胞(CSC)。在这篇综述中,我们总结了目前的证据,表明乳腺 CSC 可能部分解释了乳腺癌的内分泌抵抗。在正常乳腺中,已知干细胞具有基底表型,并且主要是雌激素受体-α阴性(ER-)。如果乳腺癌中的层次结构反映了这一点,那么乳腺 CSC 可能对内分泌治疗有抵抗性,因为它表达的 ER 非常少,只能通过来自邻近分化的 ER+肿瘤细胞的旁分泌信号来响应治疗。正常乳腺上皮干细胞受表皮生长因子受体和其他生长因子受体信号的调节。在内分泌抵抗性乳腺癌中观察到的生长因子受体表达增加可能反映了内分泌治疗选择的 CSC 比例更大。有多项研究的证据表明,乳腺 CSC 是 ER-和 EGR+/HER2+,这将支持这种观点。据报道,CSC 表达间充质基因,这些基因受 ER 表达抑制,进一步表明 ER+细胞和 CSC 之间的相互排斥。随着我们对 CSC、分化以及这些细胞中 ER 的表达和功能活性在不同乳腺肿瘤亚型中的了解不断增加,希望我们的理解将导致新的方法来克服临床中内分泌抵抗的问题。

相似文献

1
Breast cancer stem cells and their role in resistance to endocrine therapy.乳腺癌干细胞及其在抗内分泌治疗中的作用。
Horm Cancer. 2011 Apr;2(2):91-103. doi: 10.1007/s12672-011-0066-6.
2
Resistance to endocrine therapy: are breast cancer stem cells the culprits?内分泌治疗耐药:乳腺癌干细胞是罪魁祸首吗?
J Mammary Gland Biol Neoplasia. 2009 Mar;14(1):45-54. doi: 10.1007/s10911-009-9115-y. Epub 2009 Feb 28.
3
FKBPL and its peptide derivatives inhibit endocrine therapy resistant cancer stem cells and breast cancer metastasis by downregulating DLL4 and Notch4.FKBPL 及其肽衍生物通过下调 DLL4 和 Notch4 抑制内分泌治疗耐药的癌症干细胞和乳腺癌转移。
BMC Cancer. 2019 Apr 11;19(1):351. doi: 10.1186/s12885-019-5500-0.
4
PAK4 regulates stemness and progression in endocrine resistant ER-positive metastatic breast cancer.PAK4 调节内分泌抵抗型 ER 阳性转移性乳腺癌的干性和进展。
Cancer Lett. 2019 Aug 28;458:66-75. doi: 10.1016/j.canlet.2019.05.014. Epub 2019 May 20.
5
Basal/HER2 breast carcinomas: integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin).基底型/HER2 型乳腺癌:整合分子分类与癌症干细胞动力学,预测曲妥珠单抗(赫赛汀)原发性耐药。
Cell Cycle. 2013 Jan 15;12(2):225-45. doi: 10.4161/cc.23274. Epub 2012 Jan 15.
6
Oestrogen increases the activity of oestrogen receptor negative breast cancer stem cells through paracrine EGFR and Notch signalling.雌激素通过旁分泌表皮生长因子受体(EGFR)和Notch信号通路增加雌激素受体阴性乳腺癌干细胞的活性。
Breast Cancer Res. 2013 Mar 8;15(2):R21. doi: 10.1186/bcr3396.
7
Evolution of Cancer Stem-like Cells in Endocrine-Resistant Metastatic Breast Cancers Is Mediated by Stromal Microvesicles.基质微泡介导内分泌抵抗性转移性乳腺癌中癌症干细胞样细胞的演变。
Cancer Res. 2017 Apr 15;77(8):1927-1941. doi: 10.1158/0008-5472.CAN-16-2129. Epub 2017 Feb 15.
8
Acquired Resistance of ER-Positive Breast Cancer to Endocrine Treatment Confers an Adaptive Sensitivity to TRAIL through Posttranslational Downregulation of c-FLIP.获得性 ER 阳性乳腺癌对内分泌治疗的耐药性通过 c-FLIP 的翻译后下调赋予了对 TRAIL 的适应性敏感性。
Clin Cancer Res. 2018 May 15;24(10):2452-2463. doi: 10.1158/1078-0432.CCR-17-1381. Epub 2018 Jan 23.
9
∆Np63/p40 correlates with the location and phenotype of basal/mesenchymal cancer stem-like cells in human ER and HER2 breast cancers.∆Np63/p40与人类雌激素受体(ER)和人表皮生长因子受体2(HER2)阳性乳腺癌中基底/间充质样癌症干细胞的位置和表型相关。
J Pathol Clin Res. 2020 Jan;6(1):83-93. doi: 10.1002/cjp2.149. Epub 2019 Dec 6.
10
DAXX Suppresses Tumor-Initiating Cells in Estrogen Receptor-Positive Breast Cancer Following Endocrine Therapy.DAXX 抑制内分泌治疗后雌激素受体阳性乳腺癌中的肿瘤起始细胞。
Cancer Res. 2019 Oct 1;79(19):4965-4977. doi: 10.1158/0008-5472.CAN-19-1110. Epub 2019 Aug 6.

引用本文的文献

1
Intercellular communication between extracellular vesicles from conditioned macrophages and breast cancer cells drives endocrine therapy resistance.条件巨噬细胞来源的细胞外囊泡与乳腺癌细胞之间的细胞间通讯导致内分泌治疗耐药。
Front Cell Dev Biol. 2025 Jun 3;13:1548724. doi: 10.3389/fcell.2025.1548724. eCollection 2025.
2
The Therapeutic Effects of Withaferin A against Cancer: Overview and Updates.Withaferin A对癌症的治疗作用:综述与更新
Curr Mol Med. 2024;24(4):404-418. doi: 10.2174/1566524023666230418094708.
3
Higher Expressions of SHH and AR Are Associated with a Positive Receptor Status and Have Impact on Survival in a Cohort of Croatian Breast Cancer Patients.SHH和AR的高表达与受体阳性状态相关,并对一组克罗地亚乳腺癌患者的生存产生影响。
Life (Basel). 2022 Oct 7;12(10):1559. doi: 10.3390/life12101559.
4
ERα-LBD, an isoform of estrogen receptor alpha, promotes breast cancer proliferation and endocrine resistance.雌激素受体α的一种亚型ERα-LBD可促进乳腺癌增殖和内分泌抵抗。
NPJ Breast Cancer. 2022 Aug 23;8(1):96. doi: 10.1038/s41523-022-00470-6.
5
A novel group of genes that cause endocrine resistance in breast cancer identified by dynamic gene expression analysis.通过动态基因表达分析鉴定出一组导致乳腺癌内分泌抵抗的新基因。
Oncotarget. 2022 Apr 6;13:600-613. doi: 10.18632/oncotarget.28225. eCollection 2022.
6
Prolactin and endocrine therapy resistance in breast cancer: The next potential hope for breast cancer treatment.催乳素与乳腺癌内分泌治疗耐药:乳腺癌治疗的下一个潜在希望。
J Cell Mol Med. 2021 Nov;25(22):10327-10348. doi: 10.1111/jcmm.16946. Epub 2021 Oct 15.
7
Stem cell therapy: A paradigm shift in breast cancer treatment.干细胞疗法:乳腺癌治疗中的范式转变。
World J Stem Cells. 2021 Jul 26;13(7):841-860. doi: 10.4252/wjsc.v13.i7.841.
8
The Role of Forkhead Box Q1 Transcription Factor in Anticancer Effects of Withaferin A in Breast Cancer.叉头框蛋白 Q1 转录因子在醉茄素 A 抑制乳腺癌中的作用。
Cancer Prev Res (Phila). 2021 Apr;14(4):421-432. doi: 10.1158/1940-6207.CAPR-20-0590. Epub 2021 Jan 28.
9
A Comprehensive Review and Perspective on Anticancer Mechanisms of Withaferin A in Breast Cancer.白藜芦醇 A 抑制乳腺癌作用机制的全面综述与展望
Cancer Prev Res (Phila). 2020 Sep;13(9):721-734. doi: 10.1158/1940-6207.CAPR-20-0259. Epub 2020 Jul 29.
10
Notch Signaling Pathway and Endocrine Resistance in Breast Cancer.Notch信号通路与乳腺癌的内分泌耐药性
Front Pharmacol. 2020 Jun 19;11:924. doi: 10.3389/fphar.2020.00924. eCollection 2020.

本文引用的文献

1
Control of mammary stem cell function by steroid hormone signalling.甾体激素信号对乳腺干细胞功能的调控。
Nature. 2010 Jun 10;465(7299):798-802. doi: 10.1038/nature09027. Epub 2010 Apr 11.
2
Antagonistic roles of Notch and p63 in controlling mammary epithelial cell fates.Notch 和 p63 在控制乳腺上皮细胞命运中的拮抗作用。
Cell Death Differ. 2010 Oct;17(10):1600-12. doi: 10.1038/cdd.2010.37. Epub 2010 Apr 9.
3
RNAi-mediated knockdown of Notch-1 leads to cell growth inhibition and enhanced chemosensitivity in human breast cancer.RNAi 介导的 Notch-1 敲低导致人乳腺癌细胞生长抑制和化疗敏感性增强。
Oncol Rep. 2010 Apr;23(4):893-9. doi: 10.3892/or_00000712.
4
Lapatinib restores hormone sensitivity with differential effects on estrogen receptor signaling in cell models of human epidermal growth factor receptor 2-negative breast cancer with acquired endocrine resistance.拉帕替尼恢复激素敏感性,并对获得内分泌耐药的人表皮生长因子受体 2 阴性乳腺癌细胞模型中的雌激素受体信号产生差异影响。
Clin Cancer Res. 2010 Mar 1;16(5):1486-97. doi: 10.1158/1078-0432.CCR-09-1764. Epub 2010 Feb 23.
5
Selective targeting of radiation-resistant tumor-initiating cells.选择性靶向辐射抵抗性肿瘤起始细胞。
Proc Natl Acad Sci U S A. 2010 Feb 23;107(8):3522-7. doi: 10.1073/pnas.0910179107. Epub 2010 Feb 3.
6
Two distinct mechanisms underlie progesterone-induced proliferation in the mammary gland.两种不同的机制是孕激素诱导乳腺增殖的基础。
Proc Natl Acad Sci U S A. 2010 Feb 16;107(7):2989-94. doi: 10.1073/pnas.0915148107. Epub 2010 Jan 28.
7
Heterogeneity for stem cell-related markers according to tumor subtype and histologic stage in breast cancer.乳腺癌中根据肿瘤亚型和组织学分期的干细胞相关标志物的异质性。
Clin Cancer Res. 2010 Feb 1;16(3):876-87. doi: 10.1158/1078-0432.CCR-09-1532. Epub 2010 Jan 26.
8
Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content.乳腺癌的生物学和分子异质性与其癌症干细胞含量相关。
Cell. 2010 Jan 8;140(1):62-73. doi: 10.1016/j.cell.2009.12.007.
9
Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor.通过 Notch4 受体信号传导调节乳腺癌干细胞活性。
Cancer Res. 2010 Jan 15;70(2):709-18. doi: 10.1158/0008-5472.CAN-09-1681. Epub 2010 Jan 12.
10
Dynamic regulation of CD24 and the invasive, CD44posCD24neg phenotype in breast cancer cell lines.乳腺癌细胞系中 CD24 和侵袭性、CD44posCD24neg 表型的动态调节。
Breast Cancer Res. 2009;11(6):R82. doi: 10.1186/bcr2449. Epub 2009 Nov 11.